BillionToOne, Inc. Class A Common Stock (BLLN)vsIQVIA Holdings Inc (IQV)
BLLN
BillionToOne, Inc. Class A Common Stock
$98.77
+0.26%
HEALTHCARE · Cap: $4.66B
IQV
IQVIA Holdings Inc
$261.77
+1.74%
HEALTHCARE · Cap: $42.24B
Smart Verdict
WallStSmart Research — data-driven comparison
IQVIA Holdings Inc generates 4173% more annual revenue ($16.98B vs $397.41M). BLLN leads profitability with a 8.3% profit margin vs 8.1%. IQV trades at a lower P/E of 31.9x. IQV earns a higher WallStSmart Score of 55/100 (C).
BLLN
Hold38
out of 100
Grade: F
IQV
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BLLN.
Margin of Safety
+11.9%
Fair Value
$201.21
Current Price
$261.77
$60.56 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 64.4% year-over-year
Conservative balance sheet, low leverage
Every $100 of equity generates 22 in profit
Growing faster than its price suggests
Areas to Watch
Trading at 8.6x book value
0.0% earnings growth
ROE of 5.0% — below average capital efficiency
Premium valuation, high expectations priced in
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 0.6%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : BLLN
The strongest argument for BLLN centers on Revenue Growth, Debt/Equity. Revenue growth of 64.4% demonstrates continued momentum.
Bull Case : IQV
The strongest argument for IQV centers on Return on Equity, PEG Ratio. PEG of 0.97 suggests the stock is reasonably priced for its growth.
Bear Case : BLLN
The primary concerns for BLLN are Price/Book, EPS Growth, Return on Equity. A P/E of 139.1x leaves little room for execution misses.
Bear Case : IQV
The primary concerns for IQV are P/E Ratio, Piotroski F-Score, EPS Growth. Debt-to-equity of 2.63 is elevated, increasing financial risk.
Key Dynamics to Monitor
BLLN profiles as a hypergrowth stock while IQV is a value play — different risk/reward profiles.
BLLN is growing revenue faster at 64.4% — sustainability is the question.
IQV generates stronger free cash flow (360M), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
IQV scores higher overall (55/100 vs 38/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BillionToOne, Inc. Class A Common Stock
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company is headquartered in Menlo Park, California.
IQVIA Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?